- Future Students
- Current Students
- Faculty & Staff
Stuart C. Helfand
Small Animal Internal Medicine
268 Magruder Hall
541-737-4812 (hospital reception)
Professional and Research Interests:
My laboratory has a long standing interest in cancer immunotherapy and its impact on modulation of angiogenesis. We have been particularly interested in development of novel approaches to target the immunostimulatory and anti-angiogenic cytokine, interleukin-12, to vasculature within the tumor microenvironment. This work has evolved to include other approaches to suppress endothelial cell proliferation. Our current focus is on tyrosine kinase signaling pathways in malignant endothelial cells (i.e., canine hemangiosarcoma) in an effort to elucidate derangements and identify candidate aberrant kinases amenable to blockade by tyrosine kinase inhibitors. Other areas of interest include development of novel therapeutics for canine osteosarcoma.
Oregon Cancer Care for Animals (ORCCA)
Helfand SC: Canine hemangiosarcoma: A tumor of contemporary interest. Cancer Therapy. 6B:457-462, 2008
Fosmire SP, Thomas R, Jubala CM, Wojcieszyn JW, Valli VEO, Getzy DM, Smith TL, Gardner LA, Ritt MG, Bell JS et al.. 2007. Inactivation of the p16 cyclin-dependent kinase inhibitor in high-grade canine non-Hodgkin's T-cell lymphoma.. Veterinary pathology. 44(4):467-78.
Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, Breen M, Helfand SC, Modiano JF. 2005. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma.. Veterinary pathology. 42(5):618-32.
Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, Padilla M, Frazer-Abel AA, Akhtar N, Getzy DM et al.. 2004. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium.. Laboratory investigation; a journal of technical methods and pathology. 84(5):562-72.
Dickerson EB, Akhtar N, Steinberg H, Wang Z-Y, Lindstrom MJ, Padilla ML, Auerbach R, Helfand SC. 2004. Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin.. Molecular cancer research : MCR. 2(12):663-73.